# Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials
## 2 Materials and Methods
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Type of Vaccine** & **Name of Vaccine** & **Vaccine Composition** & **Start Date** & **Actual Completion** & **Phase** & **Status** &
\begin{tabular}{c} **ClinicalTrials.gov** \\ **Identifier** \\ \end{tabular} \\ \hline \multirow{7}{*}{GamTBVac} & M2/2/AS01E & Fusion protein Mh39A \& & January 2011 & July 2015 & II & Completed & NCT01262976 \\  & Mh39A, AS01E adjuvant & August 2014 & November 2018 & II & Completed & NCT01755998 \\  & & November 2020 & Est.* July 2022 & II & Recruiting & NCT04556981 \\ \cline{2-7}  & \multirow{4}{*}{GamTBVac} & Ag85A \& ESAT6-CFP10 fusion & & & & & \\  & with dextran-binding domain & January 2017 & December 2017 & I & Completed & NCT03255278 \\  & & immobilized on dextran mixed & December 2018 & May 2020 & II & Completed & NCT03878004 \\  & with adjuvant DEAE-dextran & & Est.* November & & & & & \\  & core, with CpG & 2021 & Est.* November 2025 & III & recruiting & NCT0497537 \\  & & oligodeoxynucleotides & & & & & & \\ \cline{2-7}  & \multirow{4}{*}{TB subunit vaccine} & Fusion protein of Ag85B, ESAT-6, & August 2013 & November 2015 & I/II & Completed & NCT01865487 \\  & & November 2014 & October 2016 & I & Completed & NCT02375698 \\  & & latent Rv2660c with & May 2015 & December 2016 & I & Completed & NCT02378207 \\  & & IC31 adjuvant & November 2015 & Est.* September 2019 & I & Unknown & NCT02370839 \\  & & June 2018 & Est.* June 2021 & II & Withdrawn & NCT03269977 \\  & & January 2019 & Est.* December 2024 & II & Recruiting & NCT03512249 \\ \cline{2-7}  & \multirow{4}{*}{H4:IC31} & J193 & December 2017 & I/II & Completed & NCT01861730 \\  & & February 2014 & August 2017 & II & Completed & NCT0275023 \\  & & May 2015 & October 2016 & I & Completed & NCT02378207 \\ \cline{2-7}  & \multirow{4}{*}{IB93 + ICA-SE} & September 2013 & July 2015 & I & Completed & NCT01927159 \\  & & June 2015 & January 2017 & II & Completed & NCT02465216 \\  & & October 2015 & August 2017 & I & Completed & NCT02508376 \\  & & Rv3620 with GLA-SE adjuvant & May 2018 & Est.* June 2020 & II & Active & NCT01808666 \\  & & October 2018 & June 2020 & I & Completed & NCT02372427 \\  & & April 2019 & Est.* December 2020 & I & Active & NCT03806699 \\ \cline{2-7}  & \multirow{4}{*}{AEC/BC02} & Ag85B antigen \& ESAT-6/ & April 2018 & October 2019 & I & Completed & NCT03026972 \\  & & CFF-10, BC02 adjuvant & May 2020 & Est.* August 2021 & Ib & Active & NCT01239313 \\ \hline \multirow{7}{*}{TB/FLU-01L} & \multirow{4}{*}{IIneural chicken-deficient influenza virus A 04.} & \multirow{4}{*}{Octobe 2013} & \multirow{4}{*}{February 2015} & \multirow{4}{*}{I} & \multirow{4}{*}{Completed} & \multirow{4}{*}{NCT03017378} \\  & & & expressing EST-6 antigen & & & & & \\ \cline{2-7}  & \multirow{4}{*}{4 GAB58A} & Adenovirus serotype 5 & & & & & \\ \cline{2-7}  & & expressing Ag85A & September 2017 & Est.* September 2021 & I & Recruiting & NCT02337270 \\ \cline{2-7}  & \multirow{4}{*}{ChAdOx1-85A} & Chmaborance adenoviral 85A & July 2019 & April 2016 & I & Completed & NCT01829490 \\  & & expressing Ag85A & January 2019 & August 2020 & I & Completed & NCT01421494 \\  & & July 2019 & Est.* January 2022 & I & Recruiting & NCT03681860 \\ \cline{2-7}  & \multirow{4}{*}{MVA85A} & Recombinant replication-deficient modified Vaccine virus Ankara & October 2012 & May 2015 & II & Completed & NCT0165089 \\  & & replication-deficient modified Vaccine virus Ankara & September 2015 & October 2018 & I & Terminated & NCT01954563 \\  & & expressing Ag85A & July 2019 & Est.* January 2022 & Ina & Recruiting & NCT018681860 \\ \cline{2-7}  & \multirow{4}{*}{VPM1002} & Recombinant BCG Vaccine with & June 2015 & November 2017 & II & Completed & NCT02991415 \\  & & listenyliros on encoding gene. & December 2017 & Est.* May 2022 & II/III & Recruiting & NCT03152903 \\  & & November 2020 & Est.* June 2025 & III & Recruiting & NCT04351685 \\ \hline \multirow{7}{*}{Attemated live vaccine} & \multirow{4}{*}{MTBVAC} & Attenated M. _tuberculosis_ clinical isolate with ESAT6 \& CFF10 \& & & & \\ \cline{2-7}  & \multirow{4}{*}{MIBVAC} & Attenated M. _tuberculosis_ clinical isolate with ESAT6 \& CFF10 \& & & & \\ \cline{2-7}  & & independent stable genetic & February 2019 & Est.* December 2020 & II & Unknown & NCT02933812 \\ \cline{2-7}  & \multirow{4}{*}{MTBVAC} & deletions of pho \& _fall262_ genes & Est.* July 2022 & Est.* September 2029 & III & Not yet \\ \cline{2-7}  & \multirow{4}{*}{DAR-901} & Agar-grown SRL172 by & February 2014 & June 2016 & I & Completed & NCT02063555 \\  & & scalable, broth-grown & March 2016 & February 2020 & II & Completed & NCT02712424 \\ \cline{2-7}  & \multirow{4}{*}{RUTI} & Polyantigenic liposomal vaccine & January 2019 & Est.* July 2020 & II & Unknown & NCT02711735 \\ \cline{2-7}  & & of detoxified, fragmented & Est.* September 2023 & II & Not yet & NCT04919239 \\ \cline{2-7}  & \multirow{4}{*}{M. _tuberculosis_} & 2021 & & & & & \\ \cline{2-7}  & & Vacae & Heat-killed M. _vacc_ & October 2013 & November 2017 & III & Completed & NCT01979900 \\ \hline \multirow{7}{*}{DNA vaccine} & \multirow{4}{*}{GX-70} & Antigen plasmids M. _tuberculosis_ & & & & & \\ \cline{2-7}  & & \multirow{4}{*}{KHS ligand} & March 2018 & August 2018 & I & Withdrawn & NCT03159975 \\ \cline{2-7}  & & & & & & & \\ \hline \hline \end{tabular}
\end{table}